Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures

Ono Pharmaceuticals

Status and phase: Enrolling; Phase 2

Conditions: Epilepsies, Partial

Treatments: Drug: Cenobamate

Study type: Interventional

Funder types: Industry

Identifiers

NCT06590896

ONO-2017-02

jRCT2031220198 (Registry Identifier)

Details and patient eligibility

About

To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures

Enrollment: 100 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects completed Study YKP3089C035 by SK Life Science.

Exclusion criteria

• Subjects that have previously discontinued for any reason from the Core study (YKP3089C035).
• Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Cenobamate

Experimental group

Treatment:

Drug: Cenobamate